Provided by Tiger Trade Technology Pte. Ltd.

Ligand Pharmaceuticals

284.47
-4.7800-1.65%
Post-market: 283.22-1.2500-0.44%17:17 EDT
Volume:261.16K
Turnover:74.59M
Market Cap:5.67B
PE:29.30
High:294.00
Open:291.48
Low:283.77
Close:289.25
52wk High:326.63
52wk Low:161.82
Shares:19.94M
Float Shares:19.35M
Volume Ratio:1.31
T/O Rate:1.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):9.71
EPS(LYR):6.13
ROE:21.96%
ROA:3.99%
PB:5.86
PE(LYR):46.41

Loading ...

Jul 02, 2025

Major Issues Report

Form 8-K - Current report
Jun 23, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 10, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 09, 2025

Major Issues Report

Form 8-K - Current report
May 16, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 09, 2025

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 08, 2025

Major Issues Report

Form 8-K - Current report
Apr 17, 2025

Major Issues Report

Form 8-K - Current report
Mar 19, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Mar 05, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Feb 28, 2025

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 27, 2025

Major Issues Report

Form 8-K - Current report
Feb 25, 2025

Major Issues Report

Form 8-K - Current report
Dec 23, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Nov 27, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Nov 12, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Nov 08, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 07, 2024

Major Issues Report

Form 8-K - Current report
Nov 01, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Sep 23, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities